FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912111614> ?p ?o ?g. }

• W2912111614 endingPage "251" @default.
• W2912111614 startingPage "251" @default.
• W2912111614 abstract "<h3>Importance</h3> Head and neck cancer (HNC) and its treatment may negatively alter neurocognitive and speech functioning. However, the prevalence of neurocognitive impairment among patients with HNC before treatment is poorly studied, and the association between neurocognitive and speech functioning is unknown, which hampers good interpretability of the effect of HNC treatment on neurocognitive and speech function. <h3>Objectives</h3> To document neurocognitive functioning in patients with HNC before treatment and to investigate the association between neurocognitive and speech functioning. <h3>Design, Setting, and Participants</h3> Prospective cohort study of newly diagnosed patients with HNC before treatment using a large sample obtained in a nationwide, multicenter setting (Netherlands Quality of Life and Biomedical Cohort Study in Head and Neck Cancer [NET-QUBIC] project). <h3>Main Outcome and Measures</h3> Objective neuropsychological measures of delayed recall, letter fluency, and executive functioning, as well as patient-reported outcome measures on neurocognitive speech and functioning, were collected before treatment. <h3>Results</h3> In total, 254 patients with HNC participated (71.7% male), with a mean (SD) age of 62 (10) years. The response rate ranged from 81.9% (208 of 254) to 84.6% (215 of 254). Objective neurocognitive measures indicated that 4.7% (10 of 212) to 15.0% (32 of 214) of patients were initially seen with moderate to severe cognitive impairment. Mild to moderate impairment was found in 12.3% (26 of 212) to 26.2% (56 of 214) of patients. The most altered domains were delayed recall and letter fluency. Seven percent (15 of 208) of the patients reported high levels of everyday neurocognitive failure, and 42.6% (89 of 209) reported speech problems. Objective neurocognitive function was not significantly associated with patient-reported neurocognitive or speech functioning, but the results from patient-reported outcome measures were significantly correlated. <h3>Conclusions and Relevance</h3> Results of this study demonstrate a high prevalence of impaired speech functioning among patients with HNC before treatment, which is in line with previous findings. A novel finding is that neurocognitive impairment is also highly prevalent as objectively measured and as self-perceived. Understanding the reason why patients with HNC are initially seen with neurocognitive impairment before the start of treatment is important because this impairment may complicate patient-clinician interaction and alter treatment adherence and because treatment itself may further worsen cognitive functioning. In addition, low self-perceived neurocognitive and speech functioning before treatment may decrease a patient’s confidence in communicative participation and perceived quality of life. Disentangling the associations between objective and patient-reported neurocognitive and speech functions is an important area for future research." @default.
• W2912111614 created "2019-02-21" @default.
• W2912111614 creator A5002522655 @default.
• W2912111614 creator A5003017256 @default.
• W2912111614 creator A5003786607 @default.
• W2912111614 creator A5005861774 @default.
• W2912111614 creator A5051610674 @default.
• W2912111614 creator A5055139507 @default.
• W2912111614 creator A5060987219 @default.
• W2912111614 creator A5063981653 @default.
• W2912111614 creator A5070012126 @default.
• W2912111614 creator A5078253577 @default.
• W2912111614 date "2019-03-01" @default.
• W2912111614 modified "2023-10-12" @default.
• W2912111614 title "Assessment of Neurocognitive Impairment and Speech Functioning Before Head and Neck Cancer Treatment" @default.
• W2912111614 cites W1580899029 @default.
• W2912111614 cites W1982636751 @default.
• W2912111614 cites W1982882078 @default.
• W2912111614 cites W2035805207 @default.
• W2912111614 cites W2042887543 @default.
• W2912111614 cites W2049275713 @default.
• W2912111614 cites W2063309006 @default.
• W2912111614 cites W2070600639 @default.
• W2912111614 cites W2072743331 @default.
• W2912111614 cites W2077130545 @default.
• W2912111614 cites W2083326122 @default.
• W2912111614 cites W2095183295 @default.
• W2912111614 cites W2096112597 @default.
• W2912111614 cites W2097417469 @default.
• W2912111614 cites W2103440784 @default.
• W2912111614 cites W2108427473 @default.
• W2912111614 cites W2122143074 @default.
• W2912111614 cites W2333571314 @default.
• W2912111614 cites W2396936981 @default.
• W2912111614 cites W2484842195 @default.
• W2912111614 cites W2535823818 @default.
• W2912111614 cites W2566347641 @default.
• W2912111614 cites W2621498288 @default.
• W2912111614 cites W2770716848 @default.
• W2912111614 cites W2802835704 @default.
• W2912111614 cites W2884232632 @default.
• W2912111614 cites W4242680804 @default.
• W2912111614 cites W4251522022 @default.
• W2912111614 doi "https://doi.org/10.1001/jamaoto.2018.3981" @default.
• W2912111614 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6439757" @default.
• W2912111614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30676629" @default.
• W2912111614 hasPublicationYear "2019" @default.
• W2912111614 type Work @default.
• W2912111614 sameAs 2912111614 @default.
• W2912111614 citedByCount "9" @default.
• W2912111614 countsByYear W29121116142020 @default.
• W2912111614 countsByYear W29121116142021 @default.
• W2912111614 countsByYear W29121116142022 @default.
• W2912111614 countsByYear W29121116142023 @default.
• W2912111614 crossrefType "journal-article" @default.
• W2912111614 hasAuthorship W2912111614A5002522655 @default.
• W2912111614 hasAuthorship W2912111614A5003017256 @default.
• W2912111614 hasAuthorship W2912111614A5003786607 @default.
• W2912111614 hasAuthorship W2912111614A5005861774 @default.
• W2912111614 hasAuthorship W2912111614A5051610674 @default.
• W2912111614 hasAuthorship W2912111614A5055139507 @default.
• W2912111614 hasAuthorship W2912111614A5060987219 @default.
• W2912111614 hasAuthorship W2912111614A5063981653 @default.
• W2912111614 hasAuthorship W2912111614A5070012126 @default.
• W2912111614 hasAuthorship W2912111614A5078253577 @default.
• W2912111614 hasBestOaLocation W29121116141 @default.
• W2912111614 hasConcept C118552586 @default.
• W2912111614 hasConcept C121608353 @default.
• W2912111614 hasConcept C126322002 @default.
• W2912111614 hasConcept C14216870 @default.
• W2912111614 hasConcept C159110408 @default.
• W2912111614 hasConcept C169900460 @default.
• W2912111614 hasConcept C172467417 @default.
• W2912111614 hasConcept C187212893 @default.
• W2912111614 hasConcept C2776530083 @default.
• W2912111614 hasConcept C2779951463 @default.
• W2912111614 hasConcept C536788834 @default.
• W2912111614 hasConcept C548259974 @default.
• W2912111614 hasConcept C71924100 @default.
• W2912111614 hasConcept C72563966 @default.
• W2912111614 hasConcept C97530452 @default.
• W2912111614 hasConceptScore W2912111614C118552586 @default.
• W2912111614 hasConceptScore W2912111614C121608353 @default.
• W2912111614 hasConceptScore W2912111614C126322002 @default.
• W2912111614 hasConceptScore W2912111614C14216870 @default.
• W2912111614 hasConceptScore W2912111614C159110408 @default.
• W2912111614 hasConceptScore W2912111614C169900460 @default.
• W2912111614 hasConceptScore W2912111614C172467417 @default.
• W2912111614 hasConceptScore W2912111614C187212893 @default.
• W2912111614 hasConceptScore W2912111614C2776530083 @default.
• W2912111614 hasConceptScore W2912111614C2779951463 @default.
• W2912111614 hasConceptScore W2912111614C536788834 @default.
• W2912111614 hasConceptScore W2912111614C548259974 @default.
• W2912111614 hasConceptScore W2912111614C71924100 @default.
• W2912111614 hasConceptScore W2912111614C72563966 @default.
• W2912111614 hasConceptScore W2912111614C97530452 @default.
• W2912111614 hasIssue "3" @default.
• W2912111614 hasLocation W29121116141 @default.

• next